Peptide Based Metabolic Disorders Therapeutics Market | Industry Analysis, Size, Share, Trends, Growth and Forecast 2024 – 2033 | Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc.

Overview and Scope
Peptide-based metabolic disorder therapeutics refer to pharmaceutical treatments derived from peptides short chains of amino acids that target and modulate biological pathways involved in metabolic disorders such as diabetes, obesity, and related conditions. These therapies are designed to regulate hormone levels, enhance insulin sensitivity, control appetite, and manage glucose metabolism, aiming to improve patient outcomes and quality of life.

Sizing and Forecast
The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $26.03 billion in 2023 to $29.89 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to the increasing prevalence of metabolic disorders, advancements in peptide synthess technologies, rising healthcare expenditure, a growing aging population, an expanding biopharmaceutical sector, regulatory approvals for new therapies, and increasing awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $52.16 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to the development of novel peptide analogs, rising R&D investments in metabolic disorders, adoption of precision medicine approaches, expansion of emerging markets, collaborations and partnerships in drug development, advancements in delivery technologies, and focus on patient-centric therapies. Major trends in the forecast period include the application of artificial intelligence in drug discovery, the growth of personalized therapies, the utilization of CRISPR/Cas9 for genetic therapies, the integration of wearable devices for patient monitoring, the development of oral peptide formulations, the rise of digital therapeutics in disease management, and the expansion of biobanking for personalized treatments.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Segmentation & Regional Insights
The peptide based metabolic disorders therapeutics market covered in this report is segmented –

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Major Driver Impacting Market Growth
The rising prevalence of obesity is expected to propel the growth of the peptide-based metabolic disorders therapeutic market going forward. Obesity is a medical condition characterized by excessive body fat accumulation that poses a health risk. The increasing cases of obesity are due to sedentary lifestyles, unhealthy dietary habits, genetic predisposition, and environmental influences promoting calorie-rich diets and physical inactivity. Peptide-based metabolic disorders therapeutics aim to manage conditions such as obesity by leveraging peptides to regulate metabolic functions, improve insulin sensitivity, and control appetite, thereby enhancing patient health outcomes and reducing long-term health risks associated with these chronic disorders. For instance, in May 2023, according to a report published by the Office for Health Improvement and Disparities, a UK-based governmental body, it was noted that in the period from 2021 to 2022, 63.8% of adults aged 18 years and older in England were estimated to be overweight or living with obesity, marking a slight increase from 63.3% in the previous year. Therefore, the rising prevalence of obesity is driving the peptide-based metabolic disorder therapeutics market.

Key Industry Players
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

The peptide based metabolic disorders therapeutics market report table of contents includes:

 

1. Executive Summary

2. Peptide Based Metabolic Disorders Therapeutics Market Characteristics

3. Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies

4. Peptide Based Metabolic Disorders Therapeutics Market – Macro Economic Scenario

5. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Growth

…..

32. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Benchmarking

33. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market

35. Peptide Based Metabolic Disorders Therapeutics Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model